Document Detail


Anastrozole and celecoxib for endometriosis treatment, good to keep them apart?
MedLine Citation:
PMID:  23148086     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Endometriosis is a benign gynecological disease. Cyclooxygenase-2 (COX-2) and aromatase proteins have been shown to be overexpressed in eutopic endometrium from women suffering from this disease compared to disease-free women. Furthermore, inhibition of these molecules individually was demonstrated to have antiproliferative and proapoptotic effects both in vitro and in vivo in several models. In this study, the effect of combining celecoxib, a selective COX-2 inhibitor, and anastrozole, an aromatase inhibitor, on the implantation and growth of endometriotic like lesions in a murine model of endometriosis was evaluated. Endometriosis was surgically induced in female BALB/c mice. After 28 days of treatment with celecoxib, anastrozole, or their combination, animals were killed and lesions were counted, measured, excised, and fixed. Immunohistochemistry for proliferating cell nuclear antigen and CD34 was performed for assessment of cell proliferation and vascularization. TUNEL technique was performed for apoptosis evaluation. Celecoxib was the only treatment to significantly reduce the number of lesions established per mouse, their size and vascularized area. In addition, cell proliferation was significantly diminished and apoptosis was significantly enhanced by both individual treatments. When the therapies were combined, they reversed their effects. These results confirm that celecoxib and anastrozole separately decrease endometriotic growth, but when combined they might have antagonizing effects.
Authors:
Carla N Olivares; Mariela A Bilotas; Analía G Ricci; Rosa Inés Barañao; Gabriela F Meresman
Related Documents :
23143306 - Er stress-mediated autophagy promotes myc-dependent transformation and tumor growth.
23060456 - Differential microrna (mirna) expression could explain microbial tolerance in a novel c...
23923066 - Il4 and il-17a provide a th2/th17-polarized inflammatory milieu in favor of tgf-β1 to ...
10679236 - Activation of caspase-3 in molt4 cells by apoptosis-inducing nucleosides from cd57(+)hl...
23847756 - Class i/ii hybrid inhibitory oligodeoxynucleotide exerts th1 and th2 double immunosuppr...
24561556 - Mesenchymal stem cells: immune evasive, not immune privileged.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2013-01-24
Journal Detail:
Title:  Reproduction (Cambridge, England)     Volume:  145     ISSN:  1741-7899     ISO Abbreviation:  Reproduction     Publication Date:  2013 Feb 
Date Detail:
Created Date:  2013-01-25     Completed Date:  2013-08-02     Revised Date:  2013-08-08    
Medline Journal Info:
Nlm Unique ID:  100966036     Medline TA:  Reproduction     Country:  England    
Other Details:
Languages:  eng     Pagination:  119-26     Citation Subset:  IM    
Affiliation:
Instituto de Biología y Medicina Experimental (IBYME), CONICET, C1428ADN, Ciudad Autónoma de Buenos Aires, Vuelta de Obligado 2490, Buenos Aires, Argentina. carla.olivares@ibyme.conicet.gov.ar
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Aromatase Inhibitors / administration & dosage,  adverse effects,  therapeutic use
Cyclooxygenase 2 Inhibitors / administration & dosage,  adverse effects,  therapeutic use
Drug Combinations
Drug Evaluation, Preclinical
Drug Incompatibility
Endometriosis / drug therapy*,  pathology
Female
Mesentery / pathology
Mice
Mice, Inbred BALB C
Nitriles / administration & dosage,  adverse effects,  therapeutic use*
Peritoneal Diseases / drug therapy*,  pathology
Pyrazoles / administration & dosage,  adverse effects,  therapeutic use*
Sulfonamides / administration & dosage,  adverse effects,  therapeutic use*
Triazoles / administration & dosage,  adverse effects,  therapeutic use*
Uterine Diseases / drug therapy*,  pathology
Chemical
Reg. No./Substance:
0/Aromatase Inhibitors; 0/Cyclooxygenase 2 Inhibitors; 0/Drug Combinations; 0/Nitriles; 0/Pyrazoles; 0/Sulfonamides; 0/Triazoles; 120511-73-1/anastrozole; 169590-42-5/celecoxib

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Sex selection of sperm in farm animals: status report and developmental prospects.
Next Document:  Tumour necrosis factor-? is the signal induced by mating to shutdown a 2-methoxyestradiol nongenomic...